Ποια είναι η τιμή για EQRx, Inc. (EQRX)

Η τιμή για EQRx, Inc. (EQRX) είναι $2.34

Ποια είναι η κεφαλαιοποίηση αγοράς για EQRx, Inc. (EQRX)

Η κεφαλαιοποίηση αγοράς για EQRx, Inc. (EQRX) είναι $728.90M

EQRx, Inc. (EQRX) Τιμή και Κεφαλαιοποίηση Αγοράς

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

Η τιμή για EQRX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$16,898.62 $728.90M	NVDA	$5.264T	+722,063.20%
$15,092.53 $728.90M	AAPL	$4.701T	+644,879.82%
$13,410.01 $728.90M	GOOG	$4.177T	+572,977.48%
$12,255.02 $728.90M	MSFT	$3.817T	+523,618.82%
$9,201.81 $728.90M	AMZN	$2.866T	+393,139.94%

Η τιμή για EQRX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$16,898.62 $728.90M